Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa

Research output: Contribution to journalReview article

1 Scopus citations


A 69-year-old man presents with a Dynamic International Prognostic Scoring System (DiPSS) intermediate-risk 2 post polycythemia vera myelofibrosis with significant splenomegaly, 30 pound weight loss, constitutional symptoms, and 2% peripheral blood blasts. He has no other significant past medical history and no other major comorbid conditions. You are asked by the hematology fellow you are supervising whether or not treating this patient with a Janus kinase (JAK) inhibitor will decrease major morbid events.

Original languageEnglish (US)
Pages (from-to)649-651
Number of pages3
Issue number1
StatePublished - Dec 5 2015


ASJC Scopus subject areas

  • Medicine(all)
  • Hematology

Cite this